Streetbeat News

LPTX

Leap Therapeutics, Inc.

https://www.leaptx.com

Industry

Biotechnology

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Open

2.84

Mkt cap

105M

Volume

320K

High

2.89

P/E Ratio

-2.80

52-wk high

5.00

Low

2.70

Div yield

N/A

52-wk low

1.55

Leap Therapeutics has announced a $40 million private placement to raise funds. This strategic financial move is aimed at bolstering the company's capital, potentially to further its research, development, and operational activities.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:33 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. XTL Biopharmaceuticals, Leap Therapeutics, and Jaguar Health were among the top gainers, with increases of 13.9%, 11.21%, and 10.94% respectively. On the downside, Biophytis, Fresh2 Group, and Etao International Co led the losers, with declines of 20.8%, 16.63%, and 14.01% respectively. Notably, Leap Therapeutics' rise followed its Q4 earnings release, and Avinger also reported its Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

Baird analyst Joel Beatty has maintained an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) but has lowered the price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:09 am

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Leap Therapeutics (NASDAQ:LPTX) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 10:48 am

Leap Therapeutics (NASDAQ:LPTX) reported Q4 earnings, beating estimates with an EPS of $-0.46 against the expected $-0.55. However, revenue remained unchanged from the previous year. The company had previously seen a 9.0% stock price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 3:10 pm

Leap Therapeutics (NASDAQ:LPTX) reported Q4 earnings with losses of $(0.46) per share, surpassing the analyst consensus estimate of $(0.55). This represents a 58.18% improvement over the previous year's losses of $(1.10) per share. The company also reported a cash balance of $70.6M.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 11:19 am

In Monday's after-market session, several healthcare stocks experienced significant movements. SenesTech (SNES) saw a 42.0% increase, while Centessa Pharmaceuticals (CNTA) dropped by 10.6%. Other notable gainers include TC BioPharm (TCBP), Heart Test Laboratories (HSCS), UpHealth (UPH), AcelRx Pharmaceuticals (ACRX), and Sientra (SIEN). On the losing side, Redhill Biopharma (RDHL), OneMedNet (ONMD), Tharimmune (THAR), Envoy Medical (COCH), and Leap Therapeutics (LPTX) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 9:31 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. GeneDx Holdings (WGS) saw a 39.7% increase, while Evelo Biosciences (EVLO) dropped 19.7%. Other notable gainers include Scilex Holding (SCLX), Modular Medical (MODD), Sight Sciences (SGHT), Gyre Therapeutics (GYRE), and Pasithea Therapeutics (KTTA). On the losing side, Leap Therapeutics (LPTX), SenesTech (SNES), Virios Therapeutics (VIRI), MSP Recovery (LIFW), and Biophytis (BPTS) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 5:31 pm

FLJ Group Limited's stock soared by 96.4% after announcing an agreement to acquire Alpha Mind Technology. Other stocks also saw significant movements in Friday's mid-day session, with Versus Systems Inc. leading the gainers after a strategic investment from Cronus Equity Capital Group. iRobot Corporation's stock rose due to Amazon's proposed acquisition nearing EU antitrust approval. iClick Interactive Asia Group Limited climbed after a merger deal. On the losers' side, LQR House Inc. dropped after receiving a Nasdaq delisting determination, and Impel Pharmaceuticals Inc. dipped following a recent surge.

Portfolio Pulse from Lisa Levin

November 24, 2023 | 5:21 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Fresh2 Group, Inspire Veterinary, Brainstorm Cell, Leap Therapeutics, Tivic Health Systems, and Immuneering saw their stocks rise by 18.27% to 28.4%. On the other hand, LogicMark, Connect Biopharma Hldgs, NanoString Technologies, MorphoSys, Acutus Medical, and Fortress Biotech faced declines ranging from 21.07% to 42.7%. The movements were accompanied by notable trading volumes, with some companies trading at several times their average full-day volume. MorphoSys's decline followed its Q3 earnings release four days prior.

Portfolio Pulse from Benzinga Insights

November 21, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.